Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImevaX logo — Pioneering vaccines to combat chronic and hospital-acquired...

ImevaX

Pioneering vaccines to combat chronic and hospital-acquired infections, targeting the mechanisms behind immune evasion.

Founded 2014 Series A Total: $13.40M Biotechnology, Health Care

General Information

Company Name ImevaX
Founded Year 2014
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when ImevaX moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ImevaX

ImevaX is a biopharmaceutical company founded in 2014 and based in Munich, Germany. The company is dedicated to developing targeted vaccines to combat chronic and nosocomial infections. Their lead candidate, IMX 101, focuses on combating Helicobacter pylori, a bacterium that causes ulcer disease and gastric cancer in humans by suppressing the host immune system. With a screening program targeting immune evasion mechanisms in infectious pathogens, ImevaX aims to pioneer vaccines that tackle the mechanisms behind immune evasion. The company attracted a Series A investment on March 2, 2015, marking an important milestone in its growth.

Taxonomy: Biopharmaceutical, Vaccines, Chronic infections, Nosocomial infections, Helicobacter pylori, Immune evasion, Pathogen screening, Bacterial colonization, Gastric cancer, Munich, Germany, Founder Markus Gerhard, IMX 101, Biopharmaceutical company, Infectious diseases

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• - 02 Mar 2015
Series A •••••• 4
Investor Investor Investor
•••• •••• 		28 Oct 2014
Grant •••••• 1 •••• •••• 01 Sep 2014

ImevaX Alternatives & Competitors

ImevaX vs
Cytheris
Cytheris

Advancing therapies to rejuvenate and strengthen the immune systems of patients facing cancer, chron...

Series D
Biopharma, Biotechnology
ImevaX vs
Olgram
Olgram France

Marine-inspired molecules to fight immunological diseases.

Seed
6 employees
ImevaX vs
Xinnate
Xinnate Sweden

Using the body's natural defense to promote healing

8 employees
Biopharma, Biotechnology

FAQ About ImevaX

Pioneering vaccines to combat chronic and hospital-acquired infections, targeting the mechanisms behind immune evasion.
ImevaX was founded in 2014.
ImevaX operates in the following industries: Biotechnology, Health Care.
ImevaX has completed 3 funding rounds, raising a total of $13.40M. The latest funding stage is Series A.
Top alternatives and competitors to ImevaX include Cytheris, Olgram, Xinnate, Tri-Med Global, ImmunoGenesis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImevaX and Cytheris are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ImevaX and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes